Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.54 |
| ▸ | CNR2 | P34972 | 13/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983928 | 0.94 | CNR1 (0.48) | CNR1CNR2PIK3CDSUV39H2 | |
| SCHEMBL30983559 | 0.84 | PIK3CD (0.40) | CNR1CNR2PIK3CD | |
| SCHEMBL30983844 | 0.83 | PIK3CD (0.42) | CNR1CNR2PIK3CDCKS1BSKP1 | |
| SCHEMBL30984037 | 0.82 | PDK2 (0.41) | CNR1CNR2PIK3CD | |
| SCHEMBL31321975 | 0.82 | HTR6 (0.42) | CNR1CNR2PIK3CD | |
| SCHEMBL30983884 | 0.82 | PDK2 (0.39) | CNR1CNR2PIK3CD | |
| SCHEMBL30983462 | 0.81 | PIK3CD (0.41) | CNR1CNR2PIK3CD | |
| SCHEMBL30983429 | 0.80 | CNR1 (0.44) | CNR1CNR2PIK3CD | |
| SCHEMBL30983906 | 0.79 | PIK3CD (0.39) | CNR1CNR2PIK3CD | |
| SCHEMBL30984005 | 0.79 | CFTR (0.40) | CNR1CNR2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | CNR1 4278/4885CNR2 4639/4885PIK3CD 434/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | CNR1 4278/4885CNR2 4639/4885PIK3CD 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.